Search results
Rafal Zielinski, Ph.D. Department of Experimental Therapeutics, Division of Cancer Medicine. About Dr. Rafal J Zielinski. Dr. Zielinski's research focuses on the preclinical evaluation of novel therapeutic agents that selectively target DNA and inhibitors of signaling and metabolic pathways critical for tumor development and progression.
Dive into the research topics where Rafal Jerzy Zielinski is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
Rafal ZIELINSKI | Cited by 1,207 | of University of Texas MD Anderson Cancer Center, Texas (MD Anderson) | Read 89 publications | Contact Rafal ZIELINSKI
Rafal J. Zielinski's 10 research works with 132 citations and 903 reads, including: Abstract 4947: Exploration of Annamycin Organotropism to Target Primary and Metastatic Liver Cancers
Jul 3, 2019 · Auranofin, a Food and Drug Administration–approved anti-rheumatic agent with anticancer properties for lung and ovarian cancer, has never been studied for pancreatic cancer. We hypothesize that auranofin may prevent pancreatic ductal adenocarcinoma progression by inhibition of Txnrd1 and HIF-1α.
- Mayrim V. Rios Perez, David Roife, Bingbing Dai, Michael Pratt, Ryszard Dobrowolski, Ya'an Kang, Xin...
- 10.1016/j.sopen.2019.05.004
- 2019
- Surg Open Sci. 2019 Oct; 1(2): 56-63.
To prevent cardiotoxicity, several strategies are being followed: (i) angiotensin-converting enzyme inhibitors, sartans, beta-blockers, aldosterone antagonists, and statins; (ii) iron chelators; and (iii) by development of new anthracycline derivatives with little or no cardiotoxicity.
View Rafal Zielinski’s profile on LinkedIn, the world’s largest professional community. Rafal has 1 job listed on their profile.
- 141 followers
